Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase III	Treatment	Closed	no age specified		MDA-RT-8001

Objectives

I.  Improve the overall results of treatment of adults with Hodgkin's disease 
in early stages by utilizing optimal radiotherapy and chemotherapy.
II.  Reduce the acknowledged risk of myelosuppression, sterility, and second 
tumors observed in patients treated with conventional radiotherapy and 
chemotherapy by reducing therapy to the minimal effective dosages.
III.  Design acceptable salvage therapy for patients who relapse after minimal 
therapy, in order to achieve the best possible survival rates.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with Stage I, IE, II, or IIE 
Hodgkin's disease with any histopathology or symptomatology, who have not 
received prior therapy.  Patients must agree to lymphangiogram, laparotomy, 
radiotherapy, and chemotherapy.

Expected Enrollment

Protocol closed in 1982.

Outline

Nonrandomized study.  Patients enter Regimen A if there is limited or medium 
disease, nonmediastinal (good-risk) disease, or UT nodal relapse in an 
unirradiated area following any initial treatment; patients enter Regimen A 
plus Regimen B in the case of extensive involvement, life-threatening disease, 
or poor-risk nonmediastinal disease.  All other patients receive varied 
combinations of Regimens A, B, and C.
Regimen A:  Radiotherapy.  Unspecified source to the involved field (IF), a 
unilateral or bilateral thin lung bloc (TLBI), the total abdomen, and other 
indicated areas.
Regimen B:  3-Drug Combination Chemotherapy plus Steroid Therapy.  MOPP:  
Nitrogen Mustard, NM, NSC-762; Vincristine, Oncovin, VCR, NSC-67574; 
Procarbazine, PCB, NSC-77213; plus Prednisone, PRED, NSC-10023.
Regimen C:  4-Drug Combination Chemotherapy.  ABVD:  Adriamycin, ADR, 
NSC-123127; Bleomycin, BLEO, NSC-125066; Vinblastine, VBL, NSC-49842; DTIC, 
NSC-45388.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Eugene M. McKelvey, MD, Protocol chair		Ph: 713-792-2570; 800-392-1611